Lu Qiang, Xu Jiamin, Li Qian, Wu Wenzhen, Wu Yuling, Xie Jianhui, Yang Xiaobo
Department of Pharmaceutical Sciences, Zunyi Medical University, Zhuhai Campus, Zhuhai 519041, China.
The Second School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China.
Evid Based Complement Alternat Med. 2021 Mar 16;2021:6617772. doi: 10.1155/2021/6617772. eCollection 2021.
Safflower injection (SFI), a popular Chinese patent drug, is commonly used to treat acute coronary syndromes (ACSs) in China. The research seeks to scientifically estimate the clinical efficacy of SFI for ACS patients.
Eight electronic databases were retrieved for eligible research from the founding date to September 8, 2020. Odds ratio (OR) was adopted to assess the total effective rate, ECG improvement, and adverse reaction, and mean difference (MD) was used for assessing the hemorheology indexes as well as the LVEF.
Sixteen randomized controlled trials involving 1620 sufferers with ACS were incorporated. The outcomes showed that, in comparison to conventional medication alone, SFI combined with conventional treatment remarkably enhanced the total effective rate (OR = 3.66, 95% CI [2.73, 4.90], < 0.00001), ECG improvement (OR = 2.85, 95% CI [2.04, 3.99], < 0.00001), and LVEF (MD = 5.13, 95% CI [3.73, 6.53], < 0.00001). Moreover, SFI combined with conventional treatment significantly decreased hemorheology indexes including BV (MD = -0.95, 95% CI [-1.76, -0.13], =0.02), HCT (MD = -2.37, 95% CI [-3.25, -1.50], < 0.00001), FIB (MD = -0.44, 95% CI [-0.60, -0.29], < 0.00001), and PAR (OR = -7.65, 95% CI [-10.16, -5.14], < 0.00001). However, no notable contrast was observed to link the experimental and the control team for PV (MD = -0.42, 95% CI [-0.83, 0.00], =0.05) and adverse reactions (OR = 0.59, 95% CI [0.13, 2.74], =0.50).
Despite the limitations that existed in this meta-analysis, the outcomes demonstrated that SFI and conventional combined medication is an effective and relatively safe therapy for ACS sufferers.
红花注射液（SFI）是一种常用的中成药，在中国常用于治疗急性冠脉综合征（ACS）。本研究旨在科学评估SFI对ACS患者的临床疗效。
检索了8个电子数据库，以获取从建库至2020年9月8日的符合条件的研究。采用比值比（OR）评估总有效率、心电图改善情况和不良反应，采用均差（MD）评估血液流变学指标以及左心室射血分数（LVEF）。
纳入了16项涉及1620例ACS患者的随机对照试验。结果显示，与单纯常规药物治疗相比，SFI联合常规治疗显著提高了总有效率（OR = 3.66，95%可信区间[2.73，4.90]，P < 0.00001）、心电图改善情况（OR = 2.85，95%可信区间[2.04，3.99]，P < 0.00001）和LVEF（MD = 5.13，95%可信区间[3.73，6.53]，P < 0.00001）。此外，SFI联合常规治疗显著降低了包括血黏度（BV）（MD = -0.95，95%可信区间[-1.76，-0.13]，P = 0.02）、血细胞比容（HCT）（MD = -2.37，95%可信区间[-3.25，-1.50]，P < 0.00001）、纤维蛋白原（FIB）（MD = -0.44，95%可信区间[-0.60，-0.29]，P < 0.00001）和血浆黏度（PAR）（OR = -7.65，95%可信区间[-10.16，-5.14]，P < 0.00001）在内的血液流变学指标。然而，在血浆黏度（PV）（MD = -0.42，95%可信区间[-0.83，0.00]，P = 0.05）和不良反应（OR = 0.59，95%可信区间[0.13，2.74]，P = 0.50）方面，试验组与对照组之间未观察到显著差异。
尽管本荟萃分析存在局限性，但结果表明SFI与常规联合用药对ACS患者是一种有效且相对安全的治疗方法。
